Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 24,889

Document Document Title
WO/2018/012907A1
The present invention relates to novel quinazolinone derivatives inhibiting PI3K; a method for preparing the derivatives; and a pharmaceutical composition for treating hematologic neoplasms or liver diseases, containing the quinazolinone...  
WO/2018/011376A1
A subject of the present invention is a compound having the general formula (I) a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. ...  
WO/2018/002614A1
The present disclosure relates to de novo synthesized, chemical compounds of the formula (1) or (2) that function as senescent cell detectors wherein R1, R2, R3, R4 and Z are as defined herein. The present invention also relates to proce...  
WO/2018/005533A1
This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.  
WO/2018/005660A1
Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or sym...  
WO/2018/005192A1
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...  
WO/2018/005356A1
Compounds within the scope of the present invention have a Formula 1 or a salt or produg thereof, where ring A is selected from cycloaliphatic; ring B is aryl; R1 is selected from (C1-C10)alkyl, (C3-C10)cycloalkyl, halo, aryl, and hetero...  
WO/2018/004213A1
The present invention relates to a novel compound having an SMO inhibitory activity, wherein the novel compound exhibits an excellent anticancer effect through abilities of isoindolinone and quinazolinone derivative compounds to modulate...  
WO/2017/223413A1
Disclosed herein are reversibly-switchable surfactants and methods of extracting natural products, coating surfaces, cleaning laundry, and osmotic extraction using same.  
WO/2017/219500A1
Provided is a pyrimidine compound as shown in formula I, a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. The pyrimidine compound can inhibit the activation or resistant mutation of one or more EGFRs, c...  
WO/2017/220208A1
The invention discloses a novel and selective methylation process used in the preparation of Raltegravir and intermediates. Further disclosed is an improved method for the reaction of intermediate amine compound of formula IIb with oxadi...  
WO/2017/221144A1
The present invention provides a process for preparation of Elagolix and its intermediates, processes for preparation of amorphous Elagolix sodium and solid dispersion of Elagolix Sodium thereof.  
WO/2017/216792A1
Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease...  
WO/2017/216498A1
The invention relates to the recovery of CO2 by using a reaction transforming an epoxide into cyclic carbonate using, as a catalyst, an amine of general formula (I) below or its tautomeric form. The invention also relates to the intermed...  
WO/2017/218633A1
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.  
WO/2017/212385A1
Compounds of the general formula : processes for the preparation of these compounds, compositions containing these compounds, and the compounds for use in treating cancer.  
WO/2017/214289A1
Embodiments herein are directed to topical formulations of a compound represented by the formula (I), salt, metabolite, prodrug, or hydrate thereof along with a solvent, and a base. The compound is a PDE4 inhibitor and the topical formul...  
WO/2017/214395A1
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatiti...  
WO/2017/209265A1
Provided are: a novel compound having P2X7 receptor inhibitory activity; and a pharmaceutical composition having P2X7 receptor inhibitory activity. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In ...  
WO/2017/208971A1
The present invention assembles a technology enabling production of a bicyclic nitrogen-containing heterocyclic compound directly from a nitrogen-containing heterocyclic compound through fewer steps and in a shorter period of time withou...  
WO/2017/202376A1
A sulfamide compound and a use thereof in preparing pain killers, which specifically relates to compounds as shown in formula (I) and formula (II), tautomers thereof or pharmaceutically acceptable salts thereof.  
WO/2017/202311A1
The present invention provides a polycrystalline form of a 2-aminopyrimidine. The invention specifically provides N-((5-((5-chloro-4-((naphth-2-yl)amino))pyrimidin-2-yl)amino )-2-((N-methyl-N-dimethylaminoethyl)amino)-4-methoxybenzyl)a c...  
WO/2017/205848A1
Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where...  
WO/2017/202207A1
Provided are a substituted naphthalene ring compound, and a pharmaceutical composition and an application thereof, the naphthalene ring compound being the compound shown in formula (I), or a polymorph, a pharmaceutically acceptable salt,...  
WO/2017/199028A1
A method of preparing an active agent or a salt thereof from a prodrug first compound (1) comprising a propargyl group connected to an oxygen that is directly or indirectly connected to the active agent is provided, wherein the bond betw...  
WO/2017/195216A1
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and...  
WO/2017/191000A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2017/193041A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/192929A1
The invention provides substituted pyrrolo[1,2-α]triazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gauche...  
WO/2017/192665A1
This disclosure relates to inhibitors of IRES-mediated protein synthesis, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative ...  
WO/2017/190050A1
Provided are 6-amino substituted 2,6-diamino-4-choropyrimidine compounds which are specific inhibitors of soluble adenylyl cyclase. The compounds can be formulated with pharmaceutical carriers and used for reducing cyclic AMP levels. The...  
WO/2017/187859A1
The present invention is a compound represented by formula (1), a liquid crystal composition containing the compound, and a liquid crystal display element including the composition. In the formula: R is a C1-15 alkyl or the like; ring A1...  
WO/2017/183040A1
The present invention relates to new polymorphic forms of Crystalline Rosuvastatin calcium along with novel processes for crystalline as well as amorphous Rosuvastatin calcium.  
WO/2017/183723A1
The present invention addresses the problem of providing a novel compound having a strong opening action with respect to KCNQ 2-5 channels. Provided is a compound represented by the general formula (I) (in the formula, the definitions of...  
WO/2017/184774A1
Disclosed are histone deacetylase (HDAC) inhibitors, or combinations comprising an HDAC inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of chronic lymphocytic leukemia in a subject in need thereof. Also provid...  
WO/2017/184462A1
The present disclosure relates to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-me...  
WO/2017/184956A1
Described herein are compounds that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. The compounds may allow for selective detection of Hsp90 in a sample.  
WO/2017/178344A1
This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar1 ...  
WO/2017/181177A1
The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia)...  
WO/2017/179883A1
The present specification relates to a compound expressed by the first chemical formula, and to an organic electronic element comprising same.  
WO/2017/178341A1
The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, p...  
WO/2017/179809A1
The present invention relates to: a novel compound having an excellent light-emitting ability; and an organic electroluminescent element comprising the same in one or more organic material layers, thereby having improved characteristics ...  
WO/2017/174879A1
It is an aim of the present invention to provide inhibitors of human diphtheria toxin-like ADP-ribosyltransferases, such as ARTD10, for use as a medicine. It is another aim of the invention to provide compounds for use as human mono-ADP-...  
WO/2017/175045A1
Filamenting temperature-sensitive mutant Z (FtsZ) protein plays a crucial role in the bacterial cell division machinery and is a validated drug target for antibacterial agents. The present invention relates to FtsZ-interacting compounds ...  
WO/2017/174995A1
There are provided compounds of formula I, (I) wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the fa...  
WO/2017/176756A1
A method of treating cancer in a subject in need thereof includes administering to the subject therapeutically effective amounts of a PP2A activator and a BER inhibitor, such a PARP inhibitor.  
WO/2017/176804A1
The present invention provides, in certain embodiments, compositions comprising a uniform population of free, single crystals of a hydrophobic compound. Methods of administering, and processes for preparing, compositions comprising a uni...  
WO/2017/177004A8
Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation ...  
WO/2017/177004A1
Compunds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation o...  
WO/2017/168447A4
The present invention discloses a cyclic compound of formula (I) and a process of preparation thereof. The present invention further discloses a process for the preparation of compound of formula (II) preferably Hunanamycin A from compou...  

Matches 1 - 50 out of 24,889